Kyogoku unyu shoji
9073
BlueMeme
4069
Estore
4304
Visumo
303A
D. Western Therapeutics Institute
4576
(Q1)Jun 30, 2024 | (FY)Mar 31, 2024 | (Q4)Mar 31, 2024 | (Q3)Dec 31, 2023 | (Q2)Sep 30, 2023 | (Q1)Jun 30, 2023 | (FY)Mar 31, 2023 | (Q4)Mar 31, 2023 | (Q3)Dec 31, 2022 | (Q2)Sep 30, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 5.30%25.28B | 29.85%101.26B | 25.55%26.03B | 27.81%24.9B | 37.30%26.33B | 29.11%24.01B | 9.54%77.98B | 9.39%20.73B | 8.83%19.49B | 9.84%19.17B |
Cost of revenue | 2.82%19.1B | 26.26%76.3B | 21.21%19.42B | 25.15%18.63B | 31.87%19.67B | 27.22%18.58B | 9.18%60.43B | 9.16%16.02B | 8.07%14.89B | 9.90%14.92B |
Gross profit | 13.79%6.18B | 42.23%24.96B | 40.36%6.61B | 36.43%6.27B | 56.38%6.65B | 36.03%5.43B | 10.81%17.55B | 10.17%4.71B | 11.39%4.6B | 9.62%4.25B |
Operating expense | 40.10%2.88B | 94.74%9.78B | 85.83%2.55B | 83.19%2.52B | 126.89%2.66B | 86.06%2.05B | 13.51%5.02B | 20.01%1.37B | 28.81%1.37B | 1.29%1.17B |
Staff costs | 50.57%1.31B | 75.99%4.3B | 98.46%1.18B | 73.91%1.13B | 86.78%1.11B | 45.25%872.69M | 2.79%2.44B | -7.89%596.62M | 14.04%648.58M | 3.20%594.98M |
Research and development costs | 71.93%107M | 24.21%236M | 20.72%69.79M | -14.46%59.21M | 48.11%44.77M | 90.07%62.23M | 2.94%190M | 22.96%57.81M | 39.11%69.22M | -45.68%30.23M |
Depreciation and amortization | 26.71%576M | 352.48%2.1B | 288.13%493.88M | 202.98%489.12M | 643.98%657.41M | 428.88%454.59M | 492.23%463M | 521.54%127.25M | 812.68%161.44M | 371.58%88.36M |
-Depreciation | 340.18%162M | 539.37%812M | 594.31%159.48M | 168.07%160.52M | 1,941.24%455.2M | 68.44%36.8M | 62.45%127M | 12.19%22.97M | 238.55%59.88M | 19.01%22.3M |
-Amortization | -0.91%414M | 281.85%1.28B | 220.69%334.4M | 223.57%328.6M | 206.09%202.21M | 551.72%417.79M | --336M | --104.28M | --101.55M | --66.06M |
Rent and land expenses | 17.07%168M | 64.83%628M | 65.35%164.89M | 63.87%155.12M | 74.46%164.5M | 55.42%143.5M | -1.49%381M | 4.37%99.72M | -1.14%94.66M | -4.41%94.29M |
Other operating expenses | 36.80%712M | 63.17%2.52B | 29.79%636.28M | 71.34%683.73M | 87.03%680.53M | 78.34%520.47M | 10.48%1.55B | 47.58%490.25M | 19.49%399.04M | -10.65%363.87M |
Operating profit | -2.22%3.3B | 21.19%15.19B | 21.66%4.06B | 16.52%3.76B | 29.57%3.99B | 16.92%3.38B | 9.77%12.53B | 6.58%3.33B | 5.32%3.23B | 13.15%3.08B |
Net non-operating interest income (expenses) | -27.28%-3M | -650.00%-15M | -757.42%-3.12M | -2,551.63%-4.88M | -1,211.58%-4.64M | -114.66%-2.36M | 62.90%-2M | 93.74%-364K | -434.55%-184K | -297.77%-354K |
Non-operating interest income | 161.78%3M | 40.00%7M | 291.68%2.78M | -19.91%1.22M | 10.75%1.85M | 5.14%1.15M | 21.30%5M | -29.10%709K | 70.04%1.53M | 55.14%1.67M |
Non-operating interest expense | 71.28%6M | 214.29%22M | 449.67%5.9M | 256.63%6.1M | 220.36%6.5M | 60.10%3.5M | -26.42%7M | -84.25%1.07M | 102.97%1.71M | 125.33%2.03M |
Net investment income | -53.85%6M | -8.46%119M | -324.37%-15.3M | 30.44%130.3M | -243.86%-9M | -23.65%13M | 8.73%130M | 13.33%6.82M | 4.50%99.9M | 3.82%6.26M |
Gain(Loss) on financial instruments designated as cash flow hedges | ||||||||||
Gain(Loss) on derecognition of available-for-sale financial assets | 0 | -94.80%27M | 1,616.10%29.19M | -100.03%-185K | 91.64%-1.76M | -238K | 1,369.07%519M | 95.29%-1.93M | 542M | -21.07M |
Income from associates and other participating interests | 0 | 0 | 0 | -120.93%-15M | -97.73%784K | 0 | -102.20%-413K | |||
Special income (charges) | -10M | -97.02%47M | 989.07%52.46M | -90.27%-5.46M | 0 | 0 | 6,385.40%1.58B | 56.46%-5.9M | -194.84%-2.87M | 247,802.47%1.61B |
Less:Restructuring and mergern&acquisition | --10M | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
Less:Other special charges | ---- | 97.02%-47M | -956.55%-52.46M | ---- | ---- | ---- | -26,952.97%-1.58B | 383.26%6.12M | 121.27%643K | ---1.61B |
Less:Write off | ---- | --0 | --0 | --0 | ---- | ---- | -87.88%2M | -101.43%-224K | ---- | ---- |
Other non-operating income (expenses) | 544.84%45M | -40.63%19M | -168.92%-18.77M | 60.58%-12.23M | 568.40%60.12M | -137.77%-10.12M | -52.81%32M | 426.36%27.24M | -270.44%-31.02M | -62.11%8.99M |
Income before tax | -1.25%3.34B | 4.14%15.38B | 22.03%4.09B | 0.98%3.87B | -13.86%4.03B | 16.70%3.38B | 27.25%14.76B | 7.74%3.36B | 20.13%3.83B | 68.83%4.68B |
Income tax | -25.40%1.22B | 10.07%4.89B | 5.42%1B | -18.05%985.34M | 5.07%1.27B | 50.99%1.63B | 20.03%4.44B | -0.53%949.25M | 24.31%1.2B | 41.75%1.21B |
Net income | 21.30%2.12B | 1.59%10.49B | 28.58%3.09B | 9.68%2.89B | -20.43%2.77B | -3.76%1.74B | 30.63%10.33B | 11.39%2.41B | 18.31%2.63B | 80.82%3.48B |
Net income continuous operations | 21.36%2.12B | 1.59%10.49B | 28.58%3.09B | 9.68%2.89B | -20.43%2.77B | -3.76%1.74B | 30.63%10.33B | 11.39%2.41B | 18.31%2.63B | 80.82%3.48B |
Noncontrolling interests | -53.18%26M | 113.21%226M | 114.75%61.93M | 72.17%57.07M | 98.49%51.47M | 207.04%55.53M | 31.77%106M | -5.57%28.84M | 43.56%33.15M | 44.11%25.93M |
Net income attributable to the company | 23.75%2.09B | 0.42%10.26B | 27.49%3.03B | 8.92%2.83B | -21.35%2.71B | -5.88%1.69B | 30.62%10.22B | 11.64%2.38B | 18.05%2.6B | 81.17%3.45B |
Preferred stock dividends | ||||||||||
Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Net income attributable to common stockholders | 23.75%2.09B | 0.42%10.26B | 27.49%3.03B | 8.92%2.83B | -21.35%2.71B | -5.88%1.69B | 30.62%10.22B | 11.64%2.38B | 18.05%2.6B | 81.17%3.45B |
Gross dividend payment | ||||||||||
Basic earnings per share | 23.76%27.19 | 0.74%133.29 | 27.21%39.37 | 8.58%36.69 | -20.80%35.26 | -4.69%21.97 | 33.15%132.31 | 13.83%30.95 | 21.07%33.79 | 84.35%44.52 |
Diluted earnings per share | 23.76%27.19 | 0.74%133.28 | 27.21%39.37 | 8.58%36.69 | -20.80%35.25 | -4.69%21.97 | 33.15%132.3 | 13.83%30.95 | 21.11%33.79 | 84.31%44.51 |
Dividend per share | 0 | 7.46%72 | 26.32%72 | 0 | 0 | 0 | 28.85%67 | 9.62%57 | 0 | 10 |
Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |